CellProthera prepares Phase 3 trial for first-in-class heart repair therapy

CellProthera is advancing its CD34+ stem cell therapy ProtheraCytes toward a pivotal Phase 3 trial targeting patients after myocardial infarction, aiming to prevent progression to heart failure. The company has strengthened its governance with appointments of Jérôme Hirtzlin and Anne de la Fortelle …